3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
120
HER2-positive Breast Cancer
10
Stomach Neoplasms
9
Neoplasm Metastasis
6
Neoplasms
4
Inflammatory Breast Neoplasms
4
Esophageal Neoplasms
3
Adenocarcinoma Of Esophagus
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Invasive Breast Cancer
2
HER2-positive Metastatic Breast Cancer
2
HER2-positive Early Breast Cancer
2
Colonic Neoplasms
2
Biliary Tract Neoplasms
2
Solid Tumors
1
Resectable HER2-positive Breast Cancer
1
Patient Preference
1
Pathologic Complete Response
1
Osteitis Deformans
1
Metastatic HER2-positive Breast Cancer
1
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
1
HER2-positive Gastric Cancer
1
HER2-positive Carcinoma of Breast
1
HER2-positive Advanced Breast Cancer
1
HER2+ Breast Cancer
1
HER2 Positive Early or Locally Advanced Breast Cancer
1
HER2 Positive Early Breast Cancer
1
Endometrial Neoplasms
1
Early-stage or Locally Advanced HER2-positive Breast Cancer
1
Early or Locally Advanced HER2-positive Breast Cancer
1
Interventions
pertuzumab
1
Trastuzumab
1
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Advanced HER2+Breast Cancer
×
Trastuzumab
×
Clear all
NCT04208178
2026-04-02
EPIK-B2
Novartis
Phase 3
Active not recruiting
19 enrolled